Overview

Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of escitalopram on sleep architecture utilizing a prospective design. Hypothesis: Escitalopram will improve REM latency in patients with MDD that have responded clinically to treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Sheba Medical Center
Collaborator:
Lundbeck Israel
Treatments:
Citalopram
Dexetimide